Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dwyer

Showing results (241-250 of 260) with videos related to

Pageof 26
Sort By:
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Journal of Medicinal Chemistry|December 22, 2006
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonistMichael P Dwyer, Younong Yu, Jianping Chao, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2016
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activityWensheng Yu, Craig A Coburn, De-Yi Yang, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2016
Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitorsMichael P Dwyer, Kerry M Keertikar, Lei Chen, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2016
Discovery of potent macrocyclic HCV NS5A inhibitorsWensheng Yu, Bancha Vibulbhan, Stuart B Rosenblum, et al.
Journal of Clinical and Translational Science|September 1, 2023
Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learnedDaniel F Hanley, Gordon R Bernard, Consuelo H Wilkins, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2016
Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitorsLing Tong, Wensheng Yu, Craig A Coburn, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 26, 2023
Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINTPaul E Drawz, Kristin M Lenoir, Nayanjot Kaur Rai, et al.
Lancet (London, England)|October 9, 2018
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trialErin A Bohula, Benjamin M Scirica, Silvio E Inzucchi, et al.
Pageof 26

Showing results (241-250 of 260) with videos related to

Sort By:
Pageof 26
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Journal of Medicinal Chemistry|December 22, 2006
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonistMichael P Dwyer, Younong Yu, Jianping Chao, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2016
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activityWensheng Yu, Craig A Coburn, De-Yi Yang, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2016
Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitorsMichael P Dwyer, Kerry M Keertikar, Lei Chen, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2016
Discovery of potent macrocyclic HCV NS5A inhibitorsWensheng Yu, Bancha Vibulbhan, Stuart B Rosenblum, et al.
Journal of Clinical and Translational Science|September 1, 2023
Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learnedDaniel F Hanley, Gordon R Bernard, Consuelo H Wilkins, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2016
Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitorsLing Tong, Wensheng Yu, Craig A Coburn, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 26, 2023
Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINTPaul E Drawz, Kristin M Lenoir, Nayanjot Kaur Rai, et al.
Lancet (London, England)|October 9, 2018
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trialErin A Bohula, Benjamin M Scirica, Silvio E Inzucchi, et al.
Pageof 26